PolarityTE (NASDAQ:PTE) stock is taking a beating on Tuesday after the biotechnology company got an update from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug Application (IND). Source: Odua Images via Shutterstock According to the FDA’s response, PolarityTE isn’t cleared to move forward with a pivotal study of SkinTE. This is…